Print Page  Close Window

SEC Filings

S-8 POS
VITAE PHARMACEUTICALS, INC filed this Form S-8 POS on 10/25/2016
Entire Document
 

 

EXPLANATORY NOTE / DEREGISTRATION OF UNSOLD SECURITIES

 

Vitae Pharmaceuticals, Inc. (the “Company”) is filing this Post-Effective Amendment to the following registration statements on Form S-8 (the “Registration Statements”) to withdraw and remove from registration the unissued and unsold shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and any other securities issuable by the company pursuant to the Registration Statements:

 

·                  Registration Statement on Form S-8, File No. 333-200449, filed with the SEC on November 21, 2014, pertaining to the registration of 4,860,187 shares of Common Stock for issuance under the Vitae Pharmaceuticals, Inc. 2014 Equity Incentive Plan, Vitae Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan, Vitae Pharmaceuticals, Inc. 2013 Stock Plan, Vitae Pharmaceuticals, Inc. 2004 Stock Plan and Vitae Pharmaceuticals, Inc. 2001 Stock Plan.

 

·                  Registration Statement on Form S-8, File No. 333-204625, filed with the SEC on June 1, 2015, pertaining to the registration of 901,345 shares of Common Stock for issuance under the Vitae Pharmaceuticals, Inc. 2014 Equity Incentive Plan and Vitae Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan.

 

·                  Registration Statement on Form S-8, File No. 333-209959, filed with the SEC on March 4, 2016, pertaining to the registration of 882,640 shares of Common Stock for issuance under the Vitae Pharmaceuticals, Inc. 2014 Equity Incentive Plan.

 

On October 25, 2016, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of September 13, 2016, by and among the Company, Allergan Holdco US, Inc., a Delaware corporation (“Parent”), and Augusta Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly-owned subsidiary of Parent (the “Merger”).

 

In connection with the Merger, the Company has terminated all offerings of the Company’s securities pursuant to the Registration Statements. Accordingly, the Company is filing this Post-Effective Amendment to the Registration Statements pursuant to Rule 478 under the Securities Act of 1933, as amended, to hereby terminate the effectiveness of the Registration Statements, and in accordance with the undertakings made by the Company in the Registration Statements to remove from registration, by means of this Post-Effective Amendment, any of the securities that had been registered but remain unsold at the time of the Merger, the Company hereby removes from registration all such securities, if any. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of all such securities.

 

2